Reclassifying contralateral axillary metastasis: survival benefit of aggressive local therapy challenges stage IV designation
BackgroundContralateral axillary metastasis (CAM) is currently staged as M1 (stage IV) breast cancer, guiding treatment towards palliative systemic therapy. However, emerging evidence suggests CAM may behave as a locoregional event, potentially amenable to curative-intent strategies. This study aims...
I tiakina i:
| Ngā kaituhi matua: | , , , , |
|---|---|
| Hōputu: | Artigo |
| Reo: | Inglês |
| I whakaputaina: |
Frontiers Media S.A.
2026-04-01
|
| Rangatū: | Frontiers in Oncology |
| Ngā marau: | |
| Urunga tuihono: | https://www.frontiersin.org/articles/10.3389/fonc.2026.1748851/full |
| Ngā Tūtohu: |
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!
|